HRP20110444T1 - Formulacije paratiroidnih hormona i njihove uporabe - Google Patents
Formulacije paratiroidnih hormona i njihove uporabe Download PDFInfo
- Publication number
- HRP20110444T1 HRP20110444T1 HR20110444T HRP20110444T HRP20110444T1 HR P20110444 T1 HRP20110444 T1 HR P20110444T1 HR 20110444 T HR20110444 T HR 20110444T HR P20110444 T HRP20110444 T HR P20110444T HR P20110444 T1 HRP20110444 T1 HR P20110444T1
- Authority
- HR
- Croatia
- Prior art keywords
- composition according
- poloxamer
- composition
- pth
- hpth
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 32
- 238000009472 formulation Methods 0.000 title claims abstract 8
- 108090000445 Parathyroid hormone Proteins 0.000 title claims 6
- 102000003982 Parathyroid hormone Human genes 0.000 title 1
- 239000000199 parathyroid hormone Substances 0.000 title 1
- 229960001319 parathyroid hormone Drugs 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 5
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 claims 4
- 239000000872 buffer Substances 0.000 claims 4
- 102000058004 human PTH Human genes 0.000 claims 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 239000006172 buffering agent Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000003607 modifier Substances 0.000 claims 3
- 229920001983 poloxamer Polymers 0.000 claims 3
- 229960000502 poloxamer Drugs 0.000 claims 3
- 230000001256 tonic effect Effects 0.000 claims 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229930182817 methionine Natural products 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229920005862 polyol Polymers 0.000 claims 2
- 150000003077 polyols Chemical class 0.000 claims 2
- 239000003755 preservative agent Substances 0.000 claims 2
- 230000002335 preservative effect Effects 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 239000003381 stabilizer Substances 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical group [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical group OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 229920002507 Poloxamer 124 Polymers 0.000 claims 1
- 229920002511 Poloxamer 237 Polymers 0.000 claims 1
- 229920002517 Poloxamer 338 Polymers 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 235000019445 benzyl alcohol Nutrition 0.000 claims 1
- 229930003836 cresol Natural products 0.000 claims 1
- 125000000853 cresyl group Chemical group C1(=CC=C(C=C1)C)* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 229960002885 histidine Drugs 0.000 claims 1
- 235000014304 histidine Nutrition 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 229960003646 lysine Drugs 0.000 claims 1
- 235000018977 lysine Nutrition 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 229940093448 poloxamer 124 Drugs 0.000 claims 1
- 229920001993 poloxamer 188 Polymers 0.000 claims 1
- 229940044519 poloxamer 188 Drugs 0.000 claims 1
- 229920001992 poloxamer 407 Polymers 0.000 claims 1
- 229940044476 poloxamer 407 Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 1
- 239000000811 xylitol Substances 0.000 claims 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical group OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 1
- 235000010447 xylitol Nutrition 0.000 claims 1
- 229960002675 xylitol Drugs 0.000 claims 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 3
- 239000003963 antioxidant agent Substances 0.000 abstract 2
- 230000003078 antioxidant effect Effects 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Farmaceutski sastav, naznačen time, da sadrži, kada je otopljen u pogodnom nosaču, PTH u koncentraciji od 1 mg/ml do 10 mg/ml, metionin dobavljen u koncentraciji od 1 mg/ml do 10 mg/ml, najmanje jedan poloksamerski surfaktant dobavljen u koncentraciji od 0,02 mg/ml do 1 mg/ml, i fiziološki prihvatljivo pufersko sredstvo koje održava pH formulacije na vrijednosti od pH 5 do 6,5. Patent sadrži još 18 patentnih zahtjeva.
Claims (19)
1. Farmaceutski sastav, naznačen time, da sadrži, kada je otopljen u pogodnom nosaču, PTH u koncentraciji od 1 mg/ml do 10 mg/ml, metionin dobavljen u koncentraciji od 1 mg/ml do 10 mg/ml, najmanje jedan poloksamerski surfaktant dobavljen u koncentraciji od 0,02 mg/ml do 1 mg/ml, i fiziološki prihvatljivo pufersko sredstvo koje održava pH formulacije na vrijednosti od pH 5 do 6,5.
2. Sastav prema zahtjevu 1, naznačen time, da je sastav u obliku stabilne formulacijske otopine.
3. Sastav prema zahtjevu 1 ili 2, naznačen time, da je najmanje jedan poloksamerski surfaktant odabran od Poloksamera 188, Poloksamera 407, Poloksamera 237, Poloksamera 338 i Poloksamera 124.
4. Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da je PTH odabran od hPTH(1-84) i nehumane, PTH molekule sisavca, kao i biološki aktivne varijante i homologa od hPTH(1-84) i nehumanih, PTH molekula sisavca.
5. Sastav prema zahtjevu 4, naznačen time, da sastav uključuje biološki aktivni homolog od hPTH(1-84) koji dijeli identitet sekvence sa hPTH(1-84) najmanje 85%, poželjno kada biološki aktivan homolog dijeli identitet sekvence sa hPTH(1-85) najmanje 95%, a najbolje kada biološki aktivan homolog dijeli identitet sekvence sa hPTH(1-85) najmanje 98%.
6. Sastav prema bilo kojem zahtjevu 1 do 5, naznačen time, da sadrži PTH u koncentraciji od 1,4 mg/ml, metionin u koncentraciji od 2 mg/ml, poloksamer u koncentraciji od 0,3 mg/ml, i fiziološki prihvatljivo pufersko sredstvo koje održava pH formulacije na pH 5,5.
7. Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da spomenuti sastav nadalje obuhvaća farmaceutski prihvatljivo otapalo.
8. Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da je fiziološki prihvatljivo pufersko sredstvo odabrano od citrata, acetata, fosfata, TRIS (trometamina), arginina i karbonatnih pufera.
9. Sastav prema zahtjevu 8, naznačen time, da fiziološki prikladno pufersko sredstvo je ne-isparljivi puferski agens.
10. Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da nadalje sadrži najmanje jedan tonični modifikator, posebno gdje je najmanje jedan tonični modifikator odabran od natrijevog klorida, sukroze i poliolskog ekscipijenta.
11. Sastav prema zahtjevu 10, naznačen time, da je poliolski ekscipijent odabran od sorbitola, glicerola i manitola.
12. Sastav prema bilo kojem zahtjevu 10 do 11, naznačen time, da najmanje jedan tonični modifikator ko-liofilizira sa ne-isparljivim puferskim sredstvom.
13. Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da nadalje sadrži najmanje jedan farmaceutski prihvatljivi konzervans, a najbolje kada je najmanje jedan farmaceutski prihvatljivi konzervans odabran od kresola, benzilnog alkohola i EDTA.
14. Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da nadalje sadrži najmanje jedan farmaceutski prihvatljivi stabilizator, a najbolje kada je najmanje jedan farmaceutski prihvatljivi stabilizator odabran od ksilitola, lizina, histidina i mikrokristalinične celuloze.
15. Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da je spomenuti sastav prikladan za davanje pomoću injekcije.
16. Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da je spomenuti sastav liofiliziran.
17. Postupak za pripremanje farmaceutskog sastava, naznačen time, da sadrži korake ponovnog dobivanja sastava prema zahtjevu 16 u otopini sa farmaceutski prihvatljivim nosačem.
18. Sastav prema bilo kojem zahtjevu 1 do 16, naznačen time, da se koristi kao lijek.
19. Sastav prema bilo kojem zahtjevu 1 do 16, naznačen time, da se koristi kao lijek za liječenje ili prevenciju osteoporoze.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99606107P | 2007-10-26 | 2007-10-26 | |
| EP07021017A EP2052736A1 (en) | 2007-10-26 | 2007-10-26 | Parathyroid hormone formulations und uses thereof |
| PCT/EP2008/009069 WO2009053106A1 (en) | 2007-10-26 | 2008-10-27 | Parathyroid hormone formulations and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110444T1 true HRP20110444T1 (hr) | 2011-08-31 |
Family
ID=39146901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110444T HRP20110444T1 (hr) | 2007-10-26 | 2011-06-14 | Formulacije paratiroidnih hormona i njihove uporabe |
Country Status (15)
| Country | Link |
|---|---|
| EP (2) | EP2052736A1 (hr) |
| AT (1) | ATE501725T1 (hr) |
| CY (1) | CY1112106T1 (hr) |
| DE (1) | DE602008005643D1 (hr) |
| DK (1) | DK2219665T3 (hr) |
| ES (1) | ES2363272T3 (hr) |
| HK (1) | HK1146465A1 (hr) |
| HR (1) | HRP20110444T1 (hr) |
| MX (1) | MX2010004388A (hr) |
| PL (1) | PL2219665T3 (hr) |
| PT (1) | PT2219665E (hr) |
| RU (1) | RU2467762C2 (hr) |
| SI (1) | SI2219665T1 (hr) |
| WO (1) | WO2009053106A1 (hr) |
| ZA (1) | ZA201002812B (hr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2013012349A (es) * | 2011-04-22 | 2014-07-09 | Radius Health Inc | Metodo para suministro de farmaco para pth, pthrp y peptidos relacionados. |
| EP2709645B1 (en) * | 2011-05-18 | 2023-08-09 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
| EP2785327B1 (en) | 2011-11-30 | 2023-11-22 | Kindeva Drug Delivery L.P. | Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same |
| US10591472B2 (en) | 2012-08-13 | 2020-03-17 | Minicare B.V. | Use of antioxidants in methods and means for detection of target molecules in a blood sample |
| RU2737496C2 (ru) | 2015-04-29 | 2020-12-01 | Радиус Фармасьютикалз, Инк. | Способы лечения рака |
| GB201602880D0 (en) | 2016-02-18 | 2016-04-06 | Ge Healthcare Uk Ltd | Method and composition for biomolecule stabilization |
| CN115025239A (zh) | 2016-03-01 | 2022-09-09 | 阿森迪斯药物骨疾病股份有限公司 | Pth前药 |
| AU2017336251B2 (en) | 2016-09-29 | 2024-02-22 | Ascendis Pharma Bone Diseases A/S | PTH compounds with low peak-to-trough ratios |
| AU2017336249B2 (en) | 2016-09-29 | 2024-08-01 | Ascendis Pharma Bone Diseases A/S | Dosage regimen for a controlled-release PTH compound |
| FI3565542T3 (fi) | 2017-01-05 | 2024-06-24 | Radius Pharmaceuticals Inc | Rad1901-2hcl:n polymorfisia muotoja |
| EP3685849A4 (en) * | 2017-09-22 | 2021-12-22 | Asahi Kasei Pharma Corporation | LIQUID PHARMACEUTICAL COMPOSITION CONTAINING TRIPARATIDE WITH EXCELLENT STABILITY |
| US11643385B2 (en) | 2018-07-04 | 2023-05-09 | Radius Pharmaceuticals, Inc. | Polymorphic forms of RAD1901-2HCl |
| WO2020028011A1 (en) * | 2018-07-30 | 2020-02-06 | Shire-Nps Pharmaceuticals Inc. | Formulations for improved stability of recombinant human parathyroid hormone |
| WO2020165087A1 (en) * | 2019-02-11 | 2020-08-20 | Ascendis Pharma Bone Diseases A/S | Liquid pharmaceutical formulations of pth conjugates |
| CN112439054B (zh) * | 2019-08-28 | 2023-05-16 | 深圳翰宇药业股份有限公司 | 一种特立帕肽缓释凝胶注射液及其制备方法 |
| US20230190880A1 (en) * | 2020-03-30 | 2023-06-22 | Sichuan Luzhou Buchang Bio-Pharmaceutical Co., Ltd. | Formulations of Human Parathyroid Hormone (PTH) and Methods for Producing Same |
| CN113101275A (zh) * | 2021-05-27 | 2021-07-13 | 海南通用康力制药有限公司 | 注射用棓丙酯冻干粉针剂及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69429603T2 (de) * | 1993-09-22 | 2002-08-14 | Hisamitsu Pharmaceutical Co., Inc. | Iontophoresematrix |
| ZA966075B (en) * | 1995-07-27 | 1998-01-19 | Genentech Inc | Protein formulation. |
| WO2004075913A1 (ja) * | 2003-02-28 | 2004-09-10 | Chugai Seiyaku Kabushiki Kaisha | タンパク質含有安定化製剤 |
| WO2005051456A2 (en) * | 2003-11-13 | 2005-06-09 | Alza Corporation | Composition and apparatus for transdermal delivery |
| EP1931374A2 (en) * | 2005-10-06 | 2008-06-18 | Nastech Pharmaceutical Company Inc. | Pth formulations and methods of use |
| WO2007044375A2 (en) * | 2005-10-06 | 2007-04-19 | Nastech Pharmaceutical Company Inc. | Pth formulations and methods of use |
| US8093207B2 (en) * | 2005-12-09 | 2012-01-10 | Unigene Laboratories, Inc. | Fast-acting oral peptide pharmaceutical products |
-
2007
- 2007-10-26 EP EP07021017A patent/EP2052736A1/en not_active Withdrawn
-
2008
- 2008-10-27 PT PT08842081T patent/PT2219665E/pt unknown
- 2008-10-27 PL PL08842081T patent/PL2219665T3/pl unknown
- 2008-10-27 SI SI200830278T patent/SI2219665T1/sl unknown
- 2008-10-27 MX MX2010004388A patent/MX2010004388A/es active IP Right Grant
- 2008-10-27 WO PCT/EP2008/009069 patent/WO2009053106A1/en active Application Filing
- 2008-10-27 ES ES08842081T patent/ES2363272T3/es active Active
- 2008-10-27 EP EP08842081A patent/EP2219665B1/en active Active
- 2008-10-27 DK DK08842081.5T patent/DK2219665T3/da active
- 2008-10-27 AT AT08842081T patent/ATE501725T1/de active
- 2008-10-27 DE DE602008005643T patent/DE602008005643D1/de active Active
- 2008-10-27 RU RU2010121165/15A patent/RU2467762C2/ru not_active IP Right Cessation
-
2010
- 2010-04-21 ZA ZA2010/02812A patent/ZA201002812B/en unknown
-
2011
- 2011-01-14 HK HK11100351.0A patent/HK1146465A1/xx not_active IP Right Cessation
- 2011-06-14 HR HR20110444T patent/HRP20110444T1/hr unknown
- 2011-06-16 CY CY20111100578T patent/CY1112106T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2467762C2 (ru) | 2012-11-27 |
| HK1146465A1 (en) | 2011-06-10 |
| ES2363272T3 (es) | 2011-07-28 |
| DE602008005643D1 (de) | 2011-04-28 |
| EP2219665A1 (en) | 2010-08-25 |
| SI2219665T1 (sl) | 2011-09-30 |
| ATE501725T1 (de) | 2011-04-15 |
| EP2219665B1 (en) | 2011-03-16 |
| CY1112106T1 (el) | 2015-11-04 |
| RU2010121165A (ru) | 2011-12-10 |
| ZA201002812B (en) | 2011-12-28 |
| EP2052736A1 (en) | 2009-04-29 |
| DK2219665T3 (da) | 2011-06-27 |
| WO2009053106A1 (en) | 2009-04-30 |
| PT2219665E (pt) | 2011-06-29 |
| PL2219665T3 (pl) | 2011-11-30 |
| MX2010004388A (es) | 2010-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110444T1 (hr) | Formulacije paratiroidnih hormona i njihove uporabe | |
| HRP20110801T1 (hr) | Tekući oblik fsh | |
| KR101614983B1 (ko) | Ｈｇｈ 및 ｒｈｉｇｆ―１의 조합물을 위한 제제 | |
| RU2009101226A (ru) | Составы антагониста vegf, подходящие для интравитреального введения | |
| TW201717997A (zh) | 速效胰島素組合物 | |
| US20170239335A1 (en) | Stable injectable composition of pharmaceutically active agents and process for its preparation | |
| US20130034597A1 (en) | Orally bioavailable peptide drug compositions and methods thereof | |
| PE20040560A1 (es) | Preparaciones acidas de insulina con estabilidad mejorada | |
| WO2016059592A1 (en) | Stable injectable composition of peptide drugs and process for its preparation | |
| JP4147329B2 (ja) | 液体形態の改良された安定性を有するコルチコトロピン放出因子の医薬製剤 | |
| JP2006137678A (ja) | インターロイキン−２組成物 | |
| JP2019535835A (ja) | Ｇｌｐ−１類似体の医薬組成物 | |
| KR101699677B1 (ko) | 고나도트로핀을 위한 제제 | |
| US20210187078A1 (en) | Pharmaceutical composition of insulin glargine and amino acids | |
| JP6568846B2 (ja) | Ｈｇｆ凍結乾燥製剤 | |
| ES2414705T3 (es) | Formulaciones liofilizadas de FSH/LH | |
| KR20230039783A (ko) | 거대 생리활성 물질 및 부형제를 포함하는 약학 조성물 | |
| US11737983B2 (en) | Storage stable sincalide formulations | |
| US20230190880A1 (en) | Formulations of Human Parathyroid Hormone (PTH) and Methods for Producing Same | |
| WO2023095944A1 (en) | Ultra long acting pharmaceutical composition comprising insulin | |
| CN101005851A (zh) | 含pth的经粘膜给药药剂 | |
| US20210330801A1 (en) | Novel protein drug conjugate formulation | |
| JPH08225459A (ja) | カルシトニンの注射用製剤 | |
| HRP20220817T1 (hr) | Formulacije koje sadrže rekombinantnu kiselu alfa-glukozidazu |